Li N, Mao J, Wang M, Qi J, Jiang Z, Li Y
Stem Cell Res Ther. 2024; 15(1):217.
PMID: 39020406
PMC: 11256499.
DOI: 10.1186/s13287-024-03821-1.
Park M, Kim J
Toxicol Res. 2024; 40(3):335-348.
PMID: 38911540
PMC: 11187026.
DOI: 10.1007/s43188-024-00233-4.
Kreidieh F, McQuade J
Am Heart J Plus. 2024; 40:100374.
PMID: 38510501
PMC: 10946000.
DOI: 10.1016/j.ahjo.2024.100374.
Allbritton-King J, Garcia-Cardena G
Front Cell Dev Biol. 2023; 11:1278166.
PMID: 37965580
PMC: 10642230.
DOI: 10.3389/fcell.2023.1278166.
Eaton H, Timm K
Cardiooncology. 2023; 9(1):22.
PMID: 37098605
PMC: 10127350.
DOI: 10.1186/s40959-023-00172-3.
Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy.
Mendez-Valdes G, Gomez-Hevia F, Bragato M, Lillo-Moya J, Rojas-Sole C, Saso L
Antioxidants (Basel). 2023; 12(2).
PMID: 36830015
PMC: 9952697.
DOI: 10.3390/antiox12020457.
Neuregulin-1, a potential therapeutic target for cardiac repair.
Wang Y, Wei J, Zhang P, Zhang X, Wang Y, Chen W
Front Pharmacol. 2022; 13:945206.
PMID: 36120374
PMC: 9471952.
DOI: 10.3389/fphar.2022.945206.
Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer.
Yang Z, Wang W, Wang X, Qin Z
Front Pharmacol. 2021; 12:741451.
PMID: 34790121
PMC: 8591078.
DOI: 10.3389/fphar.2021.741451.
The chicken, the egg, and the elephant: eNOS and NRG1 in fibrosis.
Nishat S, Gumina R
Am J Physiol Heart Circ Physiol. 2021; 321(2):H292-H293.
PMID: 34170198
PMC: 8410117.
DOI: 10.1152/ajpheart.00308.2021.
Nrg1β as a Proangiogenesis Therapy: How Is Nrg1β Therapy Unique From Other Angiogenesis Therapies?.
Shen Y, Abe J
Arterioscler Thromb Vasc Biol. 2021; 41(8):2315-2317.
PMID: 34162231
PMC: 8631478.
DOI: 10.1161/ATVBAHA.121.316513.
Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease.
Geissler A, Ryzhov S, Sawyer D
Clin Sci (Lond). 2020; 134(19):2623-2643.
PMID: 33063822
PMC: 7557502.
DOI: 10.1042/CS20200230.
Targeting Ca Handling Proteins for the Treatment of Heart Failure and Arrhythmias.
Njegic A, Wilson C, Cartwright E
Front Physiol. 2020; 11:1068.
PMID: 33013458
PMC: 7498719.
DOI: 10.3389/fphys.2020.01068.
Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients.
Leemasawat K, Phrommintikul A, Chattipakorn S, Chattipakorn N
Cell Mol Life Sci. 2019; 77(8):1571-1589.
PMID: 31650186
PMC: 11104997.
DOI: 10.1007/s00018-019-03340-w.
Molecular mechanisms underlying cardiotoxicity of novel cancer therapeutics.
Braumann S, Baldus S, Pfister R
J Thorac Dis. 2019; 10(Suppl 35):S4335-S4343.
PMID: 30701101
PMC: 6328392.
DOI: 10.21037/jtd.2018.10.107.
Cardiac Remodeling: Endothelial Cells Have More to Say Than Just NO.
Segers V, Brutsaert D, De Keulenaer G
Front Physiol. 2018; 9:382.
PMID: 29695980
PMC: 5904256.
DOI: 10.3389/fphys.2018.00382.
Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective.
Varricchi G, Ameri P, Cadeddu C, Ghigo A, Madonna R, Marone G
Front Physiol. 2018; 9:167.
PMID: 29563880
PMC: 5846016.
DOI: 10.3389/fphys.2018.00167.
Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways.
Sysa-Shah P, Tocchetti C, Gupta M, Rainer P, Shen X, Kang B
Cardiovasc Res. 2015; 109(3):358-73.
PMID: 26692570
PMC: 4752042.
DOI: 10.1093/cvr/cvv274.
Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening.
Kurokawa Y, George S
Adv Drug Deliv Rev. 2015; 96:225-33.
PMID: 26212156
PMC: 4869857.
DOI: 10.1016/j.addr.2015.07.004.
The roles of neuregulin-1 in cardiac development, homeostasis, and disease.
Rupert C, Coulombe K
Biomark Insights. 2015; 10(Suppl 1):1-9.
PMID: 25922571
PMC: 4395047.
DOI: 10.4137/BMI.S20061.
Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines.
Vasti C, Hertig C
World J Cardiol. 2014; 6(7):653-62.
PMID: 25068025
PMC: 4110613.
DOI: 10.4330/wjc.v6.i7.653.